Xiang Gui Yang | Clinical Microbiology | Best Researcher Award

The First Affiliated hospital of Chengdu Medical College | China

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS

Yang Xianggui embarked on his academic journey at Harbin Medical University, where he earned a Bachelor's degree in Medical Laboratory Science. He further advanced his education at Chongqing Medical University, obtaining a Master's degree in Clinical Laboratory Diagnostics from the School of Laboratory Medicine.

PROFESSIONAL ENDEAVORS

Since July 2015, Yang Xianggui has been serving as the Deputy Chief Laboratory Physician at the First Affiliated Hospital of Chengdu Medical College. His primary focus is on research into bacterial resistance mechanisms and virulence, positioning him as a significant contributor to this critical field of medical research.

CONTRIBUTIONS AND RESEARCH FOCUS ON CLINICAL MICROBIOLOGY

Dr. Yang's research endeavors have been substantial and varied, including:

CRISPR/Cas9 Technology: Utilizing CRISPR/Cas9 to knock out the ftsZ gene in bacteria to study the molecular regulatory mechanism of the key enzyme MpI in the peptidoglycan cycle.
Gene Knockout Studies: Investigating the regulatory mechanism of acute-chronic infection transformation based on the nagZ gene knockout in Enterobacter cloacae.
MicroRNA Research: Exploring the application of miR-135 in detecting early-onset chronic kidney disease.
Enzyme and Protein Studies: Examining the correlation between Klebsiella pneumoniae KPC-2 enzyme and OmpK36, and studying the molecular regulatory mechanism of AmpC beta-lactamase, a key enzyme in the peptidoglycan cycle.

IMPACT AND INFLUENCE

Dr. Yang has been the principal investigator on several high-impact research projects funded by notable organizations:

National Natural Science Youth Foundation Project: CRISPR/Cas9 technology study on ftsZ gene knockout.
Sichuan Provincial Natural Science Foundation General Project: Regulatory mechanism study on acute-chronic infection transformation.
Sichuan Provincial Department of Education Fund: Research on miR-135's application in early-onset chronic kidney disease detection.
Chengdu Medical University Fund: Correlation study between Klebsiella pneumoniae KPC-2 enzyme and OmpK36.
Special Fund of the First Affiliated Hospital of Chengdu Medical College: Study on the molecular regulatory mechanism of AmpC beta-lactamase.

ACADEMIC CITES

Dr. Yang has published nine SCI papers as the first author or corresponding author, showcasing his contributions to the scientific community. His work is recognized and cited by peers, reflecting his influence and expertise in bacterial resistance mechanisms and clinical laboratory diagnostics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yang's ongoing research projects and completed studies contribute significantly to the understanding of bacterial resistance and virulence. His legacy is built on his dedication to advancing laboratory medicine through innovative research and collaborative efforts. Future contributions are anticipated in the areas of infection control, molecular diagnostics, and bacterial resistance management, further enhancing his impact on medical science and patient care.

IMPORTANT TOPICS

BACTERIAL RESISTANCE MECHANISMS: Exploring how bacteria develop resistance to antibiotics and identifying potential targets for new treatments.
VIRULENCE FACTORS: Investigating the components that make bacteria pathogenic and how they can be neutralized.
MOLECULAR REGULATORY MECHANISMS: Understanding the intricate molecular pathways that govern bacterial behavior and resistance.
GENE KNOCKOUT TECHNOLOGIES: Utilizing advanced gene-editing tools like CRISPR/Cas9 to study bacterial genetics and physiology.
CLINICAL APPLICATIONS: Translating research findings into practical applications in clinical diagnostics and treatment strategies.

NOTABLE PUBLICATIONS

PCT, IL-6, and IL-10 facilitate early diagnosis and pathogen classifications in bloodstream infection 2023(4)

Resistance of Klebsiella pneumoniae to Phage hvKpP3 Due to High-Molecular Weight Lipopolysaccharide Synthesis Failure 2023(3)

Application of Single-Cell Genomics in Cardiovascular Research 2023(2)

Cefazolin and imipenem enhance AmpC expression and resistance in NagZ-dependent manner in Enterobacter cloacae complex 2023(3)

Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression 2021(33)

EARLY ACADEMIC PURSUITS

Since 2017, I have been dedicated to advancing the field of pharmacogenetics, beginning as a research assistant and progressing through to postdoctoral researcher at the Pharmacogenetics Laboratory of the Gregorio Marañón General University Hospital. My journey started with foundational research roles and evolved into leadership positions within various pharmacogenomic studies.

PROFESSIONAL ENDEAVORS

Starting as a research assistant, I gradually transitioned to roles as a predoctoral and postdoctoral researcher, accumulating invaluable experience and expertise in pharmacogenetics. My work has been primarily focused on pharmacogenomic studies in diverse medical areas such as colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases.

CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACOGENMICS AND PERSONALIZED MEDICINE

Throughout my career, I have actively contributed to 21 publications in pharmacogenomics, with a particular emphasis on colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases. Of these publications, I served as the first author for 14, showcasing my significant contributions to the field. Notably, my doctoral thesis in 2020 centered on intestinal inflammatory disease, underscoring my commitment to advancing knowledge in this area.

IMPACT AND INFLUENCE

My contributions have not gone unnoticed, as evidenced by receiving the AEFA (Spanish Clinical Laboratory Association) award for quality and innovation in 2019. Additionally, my research has been recognized through presentations at 20 national and international conferences, including 5 oral communications. I have been honored with the best oral communication award at three conferences, highlighting the impact of my work.

LEGACY AND FUTURE CONTRIBUTIONS

As an active member of the Spanish Society of Pharmacogenetics awards and the Spanish Association of Human Genetics, I continue to contribute to the advancement and dissemination of knowledge in these critical areas of public health. My ongoing commitment to research and collaboration ensures that my contributions will continue to shape the future of pharmacogenetics.